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There  is  considerable  interest  in  using  monoclonal  antibodies  (mAb) ~ as 
therapeutic adjuncts in treating human malignancy and in tissue transplantation 
(1,2). Several clinical trials involving tumor-specific murine mAb in the treatment 
of lymphomas (3, 4) have yielded promising results.  However, the response to 
mAb  in  several  other  studies  has  been  less  satisfactory  (5-7),  indicating  the 
presence of unknown variables that may strongly influence the outcome of such 
therapy. 
Critical to our appreciation of these variables is a better understanding of the 
interaction(s) between  mouse Ig and  the effector cells of the human immune 
system,  mAb  are  suspected  of  mediating  tumor  cytolysis,  not  by  activating 
complement (C), but by directing antibody-dependent, cell-mediated cytotoxicity 
(ADCC) (8).  Indeed, tumor-specific Ig administered to mice depleted of C  by 
cobra venom, retards the growth of transplanted tumor as readily as Ig admin- 
istered to animals with normal levels of C3 (9). Thus, the capacity of Fc receptor 
(FcR)-bearing killer (K) cells to recognize the heavy chain (H) of mouse Ig may 
be an important factor in the response to mAb therapy. 
Important in this regard is whether the H  isotype of a murine mAb influences 
its capacity to direct ADCC by human effector cells. While some investigations 
(10,  11)  indicate  that  all  mouse  mAb  isotypes  may direct  ADCC  by  human 
effector cells,  Koprowski and colleagues argue that only IgG2a  is effective, at 
least in directing ADCC by human monocytes and macrophages (12). This latter 
contention  is  supported  by  the  observation  that  cultured  human  monocytes 
interact only with murine IgG2a in ADCC (13). Moreover, Hellstrom et al. (14) 
and Imai et al. (15) have data suggesting that murine IgG2a antitumor antibodies 
are  more efficient than  IgG1  antibodies of like specificity in directing ADCC 
mediated  by  human  K  cells.  Quantitative  comparison  of different  mouse  Ig 
This work was supported by grants GM17367,  CA 04681,  and AI01897. T. J.  Kipps is a special 
fellow of the Leukemia Society of America. 
Abbreviations used in this paper:  ADCC, antibody-dependent, cell-medlated cytotoxicity; DNP, 
dinitrophenyl; E/T,  effector/target;  FACS, fluorescence-activated cell sorter;  FcR,  Fc receptor; 
FITC, fluorescein isothiocyanate; H chain, heavy chain; K, killer; mAb, monoclonai antibody; PBL, 
peripheral blood lymphocyte; RIA, radioimmunoassay. 
J. Exp. MED. © The Rockefeller University Press • 0022-1007/85/01/0001/17 $1.00  1 
Volume 161  January 1985  1-17 2  Ig  ISOTYPE  IN  HUMAN  ADCC  DIRECTED  BY  MURINE  mAb 
isotypes for their ability to direct ADCC, however, has not been possible, because 
each of the mAb tested has been an independent hybridoma product with unique 
target antigen fine specificity and affinity. Precise analysis of the role of isotype 
in  mediating  ADCC  would  require  mAb  of different  isotypes  with  identical 
binding sites, to exclude the possibility that differences in the binding specificities 
or affinities are responsible for differences in ADCC. 
mAb fulfilling this requirement can be generated by selecting switch variant 
hybridoma cells which spontaneously express an  H  isotype different from that 
of the parent hybridomas, but retain expression of the same  H  variable region 
and light chains (16-18). Ig produced by members of such switch variant families 
have identical reactivities with antigens and differ only in isotype, thus permitting 
study of the dependence of isotype in ADCC with no other antibody variables. 
Our present studies on ADCC mediated by human peripheral blood lymphocytes 
(PBL) are  directed  by  IgGl,  IgG2b,  or  IgG2a  produced  by members  of two 
switch  variant  families  specific for two  HLA  antigens  expressed  by cells  of a 
human B iymphoblastoid line, JY. 
Materials and Methods 
Cells.  The human  B iymphoblastoid cell line, JY, was used as the target cell in the 
ADCC assay. This cell expresses HLA antigens A2, B7, and DC-1 (19). ME1 and MA2.1 
are murine hybridoma cell lines.  ME1, developed by Ellis et al.  (20),  secretes an IgGl 
with high affinity to HLA-B7, Bw22, Bw42, and B27. In addition to these strong reactions, 
this antibody cross-reacts weakly with HLA-B14 and a few other HLA-B locus products. 
MA2.1  secretes an IgG1  with high affinity for HLA-A2 and B17 (21). We selected the 
lgG2a and IgG2b isotype switch variants of ME1 and MA2.1 from their respective parent 
IgGl-producing hybridomas using the fluorescence-activated cell sorter (FACS), as de- 
scribed below. Cells were cultured in RPMI 1640 (Gibco Laboratories, Grand Island, NY) 
supplemented with  15% fetal calf serum (FCS) and 2 mM glutamine, and maintained at 
37°C in a humidified atmosphere with 7% CO2 in air. 
Monoclonal Antibodies.  mAb specific for Leu-2a, Leu-7, Leu-lla, and  Leu-15 were 
gifts from the Becton Dickinson Monoclonal Center, Inc. (Mountain View, CA). Mo2 was 
the gift of Coulter Immunology (Hialeah, FL). The IgG1 anti-DNP (dinitrophenyl) mAb 
and Texas Red-avidin were the gifts of Dr. R. Hardy (Genetics Dept., Stanford University, 
Palo Alto, CA).  Antibodies 8.3, reactive with Igh-la, and 21-48.3, reactive with Igh-la, 
3a, are as described (22). 
Fluorochrome Conjugation of  Antibodies.  Isotype-specific goat anti-mouse antibodies and 
mAb 8.3 were conjugated to fluorescein isothiocyanate (FITC) as described by Goding 
(23). 
Multiparameter FACS Analysis.  Immunofluorescence and light scatter analysis of PBL 
were performed on a dual laser FACS II as described (24). Fluorescein and phycoerythrin 
were excited at  488  nm  by an  argon  laser.  Texas Red was  excited by an  adjustable 
rhodamine dye laser at 600 nm. 
3  51  ADCC Assay.  80-t~l  aliquots cohtaining 5 ×  10"  Cr-labeled JY target cells in RPMI 
1640 culture medium with 10% heat-inactivated FCS were added to individual wells of a 
96-well V-bottom microtiter plate.  Purified antibody (from which aggregates wei'e re- 
moved by centrifugation in a Beckman airfuge for 15 rain at 30 psi) was added to each 
well in 20 #1 isotonic phosphate-buffered saline (PBS), pH 7.4 to the final concentrations 
specified in the text. We incubated the cells with antibody for 20 min at room temperature, 
before adding  100 #1 of effector cells in culture medium to each well,  at the specified 
effector/target (E/T) ratio. The plates were spun for 5 min at 200 g, and subsequently 
placed in a 37 °C incubator with humidified 7% CO~ in air. At times indicated in the text, 
the plates were again spun for 5 rain at 200 g and 100/~i of supernatant were harvested 
from each well. Samples were counted in a Beckman gamma scintillation counter. Wells KIPPS  ET  AL.  3 
oflabeledJY with neither antibody or effector cells served as spontaneous release controls. 
Control wells  of labeled JY with either antibody or effector cells were included in each 
experiment. Maximum counts were from wells of iabeledJY to which we added 100 #1 of 
5% Triton-X (Sigma Chemical Co., St. Louis, MO) instead of effector cells.  The percent 
specific release was determined by the formula: [(sample -  spontaneous release)/(maxi- 
mum counts -  spontaneous release)] x  100. All samples were done in triplicate. Standard 
deviation of the mean for a given sample was calculated using an unbiased estimator for 
small samples (25). 
Isolation of Effector Cells for ADCC.  Blood  samples  from  healthy  volunteers  were 
gathered in heparinized syringes and diluted  1:1 with RPMI  1640 at room temperature. 
Leukocytes were isolated on FicolI-Hypaque (Pharmacia, Inc., Uppsala, Sweden) density 
gradients  (0  =  1.08  g/ml).  Mononuclear  cells were harvested and  washed three  times 
before assay.  Cell  viability, as assessed  by staining with  acridine orange and  ethidium 
bromide, was >95%.  Where indicated,  adherent cells were removed by incubating the 
isolated PBL on plastic culture dishes (Falcon Labware, Oxnard, CA) for 2 h at 37°C in 
culture medium supplemented with 10% heat-inactivated FCS. 
Radioiodination of Antibodies.  Purified anti-Igh la (8.3) or goat anti-mouse IgG mAb 
was radiolabeled with 12~I using the method of Hunter and Greenwood (26). 
Solid Phase Radioimmunoassay (RIA).  mAb 21-48.3,  anti-Igh  la,3a (22),  was used to 
coat polystyrene microtiter plates as described (27). After incubation with varying dilutions 
of culture supernates, and subsequent washing to remove unbound antibody, radiolabeled 
8.3 (anti-lgh la) or goat anti-IgG2b was used to detect IgG2a or IgG2b, respectively. 
Preparation oflg and Antibody Fragments.  Antibodies were isolated from the ascites of 
hybridoma-bearing mice by ammonium sulfate salt precipitation and subsequent DEAE, 
then Sephadex G-200 size chromatography. The IgG2a and IgG2b MA2.1 were purified 
using Staph A-Sepharose in lieu of G-200 Sephadex chromatography as described (28). 
The  Fab'  and  the  F(ab')2  of the  IgG1  ME1  were  prepared  as  described  (29).  Goat 
antibodies specific for either mouse IgG1 or IgG2 were prepared as reported previously 
(SO). 
8witch Variant Selection.  IgG 1-producing parent hybridoma cell lines MA2.1 and ME 1 
bad been growing in  tissue culture a  minimum of 4  mo without subcloning.  Since the 
proportion of switch variants within a given hybridoma population will generally increase 
with time (31), these lines were not subcloned before selection. Switch variant selection 
with fluorescein-conjugated antibodies specific for mouse IgG2 (goat anti-mouse IgG2) or 
IgG2a (mAb 8.3) was performed on a modified FACS II (B-D FACS Systems, Sunnyvale, 
CA) using a cloning apparatus that permits pauci-population sorting as described (18, 31). 
We took care that cell populations used for switch variant selection were >95%  viable 
before staining. In addition, propidium iodide was used to stain dead cells so they could 
be excluded from FACS analysis and sorting (17). Pauci-population sorting permitted the 
cloning of switch variants after one round of selection. Culture supernatants of wells into 
which  1, 5, 25, or  100 brightly fluorescent ceils had been sorted were screened using a 
solid phase  RIA for detection  of the variant isotype. Cells that scored positive for the 
variant isotype were then stained again with  FITC-goat anti-mouse IgG2 or FITC-8.3 
(anti-Igh 1  a). Single, stained cells were deposited into individual wells of microtiter plates. 
The proportion oflgG2b or IgG2a variants in either the ME1 or MA2.1 parent hybridoma 
populations was calculated by multiplying the initial sort frequency by the percentage of 
cells identified as being switch variants in the sorted plates, using the Poisson distribution 
to calculate the number of variants per plate from data obtained in the RIA (18, 31). 
Cell-binding Assays.  Radio-immune cell-binding assays to quantitate bound antibody 
were performed as described (32).  Fluorescence-immune cell-binding assays to quantitate 
mouse antibody bound to JY were performed using FITC-conjugated goat anti-mouse Ig 
to stain  washed  cells that  had  been  incubated  for  20  rain  with  anti-HLA at  specified 
concentrations. Propidium iodide at 1 #g/ml was used to stain dead cells so they could be 
excluded  electronically  from  FACS  analysis.  Fluorescence data  were collected  using a 
modified FACS II equipped with logarithmic amplifiers. The mean fluorescence of 104 
cells  from each  sample was  subsequently  converted  to  linear  units  for comparison  of Ig  ISOTYPE 1N  HUMAN ADCC DIRECTED BY  MURINE mAb 
fluorescence intensity  between samples. The percent of maximal binding was calculated 
by dividing this value by the maximum mean fluorescence value achieved with a saturating 
concentration of tested antibody. 
Results 
Isolation  of Switch  Variant  Families.  The  IgGl-producing  hybridomas  ME1 
and MA2.1  were initially stained with isotype-specific, FITC-labeled, goat anti- 
mouse  antibodies  and  found  to  be  90  and  97%  positive  for  surface  IgG1 
expression, respectively. Except for an extremely small fraction of cells in either 
population,  no  appreciable  staining  with  goat  anti-mouse  IgG2  antibody  was 
detected. The proportion  of IgG2b switch variants within the ME1  hybridoma 
population, however, was high enough to permit direct cloning during the first 
round  of variant  selection  (Table  I).  The  IgG2a  ME1,  and  IgG2b and  IgG2a 
MA2.1  switch  variants  were  cloned  from  sorted  pauci-populations  found  to 
producing switch variant antibody by RIA. >95% of the cells from each cloned 
switch variant line stained positively for the newly acquired variant isotype using 
isotype-specific, FITC-conjugated antibody. Furthermore, <1 per 105 cells from 
such cloned switch variant lines stained for the parent surface IgG1. 
Quantitative Binding of Purified Antibodies Produced by the Switch Variant Fami- 
lies.  Purified IgG1,  IgG2a, and IgG2b of the ME1  switch variant family were 
compared  by a  radio-immune  cell-binding  assay to  verify that  no changes  in 
either the specificity or avidity of the antibodies accompanied the isotype switch. 
As seen in  Fig.  1 a,  titration  of all three isotypes against a  fixed number of JY 
cells in an indirect trace-binding assay gave superimposable binding curves. The 
same assay, using a  single saturating  concentration  of IgG (25 t~g/ml),  demon- 
strated that the binding of each ME1 isotype, to a panel of 12 B lymphoblastoid 
cell  lines  of different  HLA  types,  was  the  same  (data  not  shown).  Similarly, 
titration  of the  MA2.1  switch variant  family of antibodies,  in a  fluorescence- 
immune  cell-binding assay, demonstrated  that  all three have  identical  binding 
activities for JY (Fig.  1 b). These results confirm that the switch in the H constant 
region from IgG1  to IgG2a or IgG2b has no discernible effect on the antigen- 
combining  site of these anti-HLA antibodies.  Thus,  the  Ig produced by these 
TABLE  I 
Number of lsotype Switch Variants Detected in Hybridoma 
Populations 
Average number of variants (X 10  -8) 
Hybridoma cell line 
IgG2b  IgG2a 
ME1  1,600  64 
MA2.1  32  8 
Selection of switch variant families. Brightly fluorescent cells from 3 x 
108 hybridomas of either cell line stained with F1TC-goat anti-mouse 
IgG2 were sorted into individual wells of microtiter plates using the 
technique of pauci-population sorting. Wells containing variants of either 
subclass  were subsequently  identified using a solid phase RIA. The average 
number of variants per sorted plate was calculated using the  Poisson 
distribution. KIPPS  ET  AL. 
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FIGURE  l.  Titration of antibodies from switch variant families with JY: IgG1,  IgG2a, and 
lgG2b antibodies of the ME1  switch variant family (left),  or the MA2.1  family (right),  were 
125  titered with a fixed number of JY. Specifically bound antibody was detected with  I-labeled 
goat anti-mouse  Ig  (left),  or  with  FITC-labeled goat  anti-mouse  Ig (right),  for  the  radio- 
immune, or fluorescence-immune cell-binding assays, respectively. IgG1 (O), lgG2a (A), lgG2b 
(D). 
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FIGURE 2,  ADCC of IgG2a ME1  antibody: 5~Cr-labeled JY was  incubated with or without 
IgG2a ME1 at  10 ~g/ml, as described in Materials and Methods. PBL were added to an E/T 
ratio of 100:1.  Bars indicate standard  deviation (+SD) of percent specific lysis for triplicate 
samples. 
switch variant families were judged suitable for examining the effects of isotype 
on ADCC. 
Antibody-dependent  Cell  Cytotoxicity.  Our  preliminary  studies  demonstrated 
that the IgG2a ME1 can direct significant ADCC of  JY by freshly isolated human 
PBL. Specific lysis of antibody-coated JY increased linearly with time, reaching 
a maximum of ~60% iysis in the 6 h period (Fig. 2). No significant lysis occurred 
in the absence of antibody, nor with nonspecific IgG2a antibody. Furthermore, ]g  ISOTYPE  IN  HUMAN  ADCC  DIRECTED  BY  MURINE  mAb 
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FIGURE 3.  Comparison of ADCC activities of different antibody isotypes of ME1. Antibody 
at various concentrations was added  to 51Cr-labeled  JY. Percent specific lysis (+SD) is of JY 
after 4 h incubation with PBL at an E/T ratio of 50:1. lgG1 (Q), IgG2a (/k), IgG2b (I--1). 
IgG2a ME1 did not direct lysis of Daudi cells lacking HLA-B7 (data not shown). 
These results demonstrate that lysis is due to ADCC. For comparing the different 
isotypes, an incubation time of 4 h was chosen. 
Comparison of ADCC Activity Directed by Different Isotypes.  ADCC directed by 
IgG1, IgG2b, and IgG2a ME1 antibodies at a constant E/T ratio revealed that 
IgG2a provides the highest level of ADCC activity, effecting a maximal specific 
lysis  of 25  +  2%  at  antibody  concentrations >2  ~tg/ml  (Fig.  3).  The  IgG2b 
subclass is significantly less effective, directing only 10 +_ 2% maximal lysis of  JY. 
The fraction of maximal lysis directed by IgG2b and IgG2a at various concen- 
trations, however, are the same, consistent with these antibodies having identical 
binding affinities for theJY target cell. In contrast, no specific lysis of  JY sensitized 
with IgG1  ME1  was detected, even at high antibody concentrations, and even 
when the assay time was extended to 19 h. Furthermore, cells killed with IgG2b 
ME1 increased with time, but remained significantly less than that of the IgG2a- 
coated JY at all time points tested (Fig. 4). 
We  obtained similar results  with  the  MA2.1  switch variant family (Fig.  5). 
IgG2a  MA2.1  directed two- to threefold greater cell dependent lysis of JY at 
matched concentrations of IgG2b MA2.1, and IgG1 antibody gave no significant 
ADCC. 
Quantitation of Antibody Molecules Binding JY.  Radiolabeled IgG2a ME1  was 
titered with JY  under conditions identical to those used in the ADCC experi- 
ments. Reaching half-saturation at I /~g/ml, the binding curve closely paralleled 
ADCC  activity.  This  demonstrates that  a  large proportion  of the total  HLA 
target  molecules on JY  must  be  bound  by  antibody  for effective ADCC.  At 
saturation,  5  X  10 6  Ig  molecules bound.  This  approximates  the  number  of 
surface HLA molecules perJY cell (33). 
Inhibition oflgG2a ADCC.  ADCC directed by IgG2a ME1 is inhibited equally 
well by IgG1 ME1 or F(ab')2 ME1, on a molar basis (Fig. 6). This result confirms 
that the Fc domains of these antibodies are crucial for directing ADCC activity. KIPPS  ET  AL. 
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FIGURE 4.  Kinetics of ADCC directed by the different isotypes of MEI. 5~Cr-labeledJY was 
incubated with antibody of each isotype at 10 gg/ml. ADCC (__SD) of PBL at an E/T ratio of 
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FIGURE 5.  ADCC  activities of different antibody isotypes of MA2.1.  S~Cr-labeled JY  was 
incubated with antibody of each isotype at various concentrations. Percent specific lysis (_SD) 
is of JY after 4  h  incubation with PBL at an E/T ratio of 50:1. IgG1  (Q),  IgG2a (Ix), IgG2b 
CO). 
The Fab'  of ME1  is much less effective in blocking ADCC directed by IgG2a 
ME1, presumably because of the lost avidity of the univalent Fab' molecules. 
Comparable results for the inhibition of IgG2a-directed ADCC by IgG1  was 
noted in the MA2.1  system. 50%  inhibition of ADCC directed by 4  t~g/ml of 
IgG2a MA2.1  (2.7 X  10 -8 M) was achieved with an equimolar concentration of 
IgG1  MA2.1.  IgG1  ME1, however, did not block ADCC directed by the non- 
cross-reacting IgG2a  MA2.1.  Moreover,  IgG1  MA2.1  did  not  inhibit  IgG2a 
MEl-directed ADCC. These results confirm that inhibition with IgG1 is due to 
specific competition for binding to target HLA molecules, not in the interaction 
with effector (K) cells. 
Comparison of  ADCC Activity in Different Individuals.  Although there is consid- 
erable variability in the levels of ADCC activity observed with PBL isolated from 
different people,  the relative capacities of the three Ig isotypes for directing 
ADCC were unchanged (Fig.  7). IgG2b ME1  directed levels of ADCC interme- 
diate to those of IgG2a, and the IgG 1 ME 1 was always ineffective. Furthermore, lg  ISOTYPE  IN  HUMAN  ADCC  DIRECTED  BY  MURINE  mAb 
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FIGURE 6.  Inhibition of IgG2a ME1  ADCC. The Fab', F(ab')2, or IgG1  of ME1  was added, 
at  various  concentrations, to  separate  wells  containing ~Cr-labeled JY.  lgG2a  ME1  was 
subsequently added to 2.5 ttg/ml. After a 20 min incubation at room temperature, PBL were 
added to an E/T ratio of 50:1. ADCC was measured after 4 h  incubation at 37°C. Samples 
without inhibitor had 30% (_+ 1%) specific lysis of  JY with the lgG2a ME1. Percent inhibition 
of ADCC was determined by comparing the percent specific lysis of each sample with this 
value. IgG1  (e), F(ab')2 (&), Fab' (A). 
60 
(a)  ~-(b)  (c)  ~  IgG1 
50  ~  o  IgG2a 
•  IgG2b 
40 
2O 
60 
(d)  (e)  (f) 
Z  50  uJ 
u 
~  4o 
30 
20 
,,  ,  ,  ~  ,  ,  ,,  ,  , 
4  20  100  4  20  100  4  20  100 
E/T RATIO 
FmURE  7.  Comparison of ADCC activities of IgGI, IgG2a, and IgG2b ME I with PBL from 
different individuals. Antibodies of each isotype were incubated with SlCr-labeled  JY at 5 ug/ 
ml. PBL from each individual were added at various concentrations to yield E/T ratios of 4, 
20, or 100:1.  Samples were assayed after 4 h incubation at 37°C. IgGl (ZX), IgG2a (O), IgG2b 
(O). KIPPS  ET  AL.  9 
the  maximum levels of ADCC  with  IgG2b at  different E/T  ratios  tended  to 
parallel the levels found with IgG2a at these E/T ratios. 
Characterization of Effector Cells.  To assess the ADCC activity of PBL depleted 
of monocytes, we compared the activity of unfractionated  PBL with PBL not 
adhering  to  plastic  after  2  h  incubation  at  37°C.  These  nonadherent  cells 
represented -85% of the freshly isolated mononuclear cells, were >98% free of 
monocytes (assessed  by  morphology after  staining  with  Wright-Giemsa),  and 
possessed all  the ADCC activity of the total  mononuclear PBL.  This suggests 
that the PBL effector cells are nonadherent K cells (34). 
Several  groups  of investigators  (35-37)  have  reported  the  development of 
mAb that are specific for surface molecules expressed by human K cells. Some 
of these antibodies have been found to specifically block K cell ADCC activity, 
presumably by binding the Fc receptors of such cells (35,  37). Prior incubation 
of mononuclear cells with one such anti-FcR antibody, anti-Leu-1 la, abrogated 
the ADCC activity of the PBL for IgG2a-coatedJY (Table II). Other antibodies, 
anti-Leu-2a,  anti-Leu-7,  and anti-Leu-15,  which reportedly bind to  human K 
cells but do not block the FcR (38-40), gave no inhibition of ADCC directed by 
IgG2a anti-HLA of either specificity. Furthermore, murine IgG1 anti-DNP mAb 
of the same isotype as the anti-Leu-1 la gave no inhibition of ADCC. Comparable 
results  were  obtained  with  IgG2b  ME1-and  IgG2a  MA2.1-directed  ADCC 
(data not shown). 
Multiparameter fluorescence and light scatter analysis of PBL confirms that 
ceils expressing Leu-1 la have the forward and obtuse angle light scatter char- 
acteristics of large lymphocytes, which can  readily be distinguished from cells 
expressing Mo2, a  monocyte differentiation antigen (41).  The light scatter of 
whole, ungated PBL is shown in Fig. 8a. A box enclosing 95% of the Leu-1 la ÷ 
cells (Fig.  8b)  excludes 96%  of Mo2-expressing monocytes (Fig.  8c).  All cells 
TABLE  II 
Inhibition of ADCC by Anti-FcR Antibody 
IgG2a ME1  Antibody  added to effector  ADCC (+_.SD)  added to JY  cells 
+  --  29 (2) 
+  Anti-Leu-2a  25 (3) 
+  Anti-Leu-7  28 (2) 
+  Anti-Leu-1 la  2 (3) 
+  Anti-Leu-I 5  27 (2) 
+  Anti-DNP  25 (3) 
-  --  o(1) 
-  Anti-Leu-2a  2 (2) 
-  Anti-Leu-7  2 (1) 
-  Anti-Leu-I la  0  (1) 
-  Anti-Leu-15  1 (1) 
-  Anti-DNP  0 (1) 
Inhibition of ADCC by anti-FcR: 5JCr-labeled JY were incubated with or 
without IgG2a MEI at 4 #g/ml. PBL were incubated with 1.5 #g/10  s cells 
of mAb at 25 #g/ml for 20 rain at room temperature.  PBL were washed 
free of unbound antibody and added to JY at an E/T ratio of 50:1. ADCC 
was assayed after 4  h  incubation at 37°C. I
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FIGURE 9.  Cell surface antigen distribution of Leu-I la  + cells.  PBL were stained with phy- 
coerythrin-conjugated anti-Leu-15,  FITC-labeled anti-Leu-1 la, and  biotin-conjugated anti- 
Leu-2a  (a and  b) or  biotin-conjugated anti-Leu-7  (c and  d).  After washing away  unbound 
antibody, cells were stained with Texas Red-avidin as a second step. a and c demonstrate the 
staining of ungated  lymphocytes with anti-Leu-15/anti-Leu-2a, and anti-Leu-15/anti-Leu-7, 
respectively, b and d depict the distribution of cell surface antigens on the 10% of cells staining 
positively for Leu-I la. Numbers on the ordinate and abscissa  indicate relative fluorescence 
intensity. 
expressing Leu-1 la also express Leu-15 (Fig. 9,b and d), the receptor for C3bi 
(42).  Approximately half of the  Leu-1 la + cells stained dully with anti-Leu-2a 
(Fig. 9b), and less than half stained positively with anti-Leu-7 (Fig. 9d). 
To enrich  for  cells  expressing  Leu-1 la  without staining  with  anti-Leu-I la 
antibody,  PBL  were  stained  with  phycoerythrin-conjugated  anti-Leu-15  and 
sorted into separate subpopulations based on light scatter and fluorescence. PBL 
depleted of monocytes by FACS sorting (based on light scatter) possessed ADCC 
activity comparable to, or greater than, PBL from unsorted populations (Table 
III). Lymphocytes expressing Leu-I 5, however, had even greater ADCC activity. 12  lg  ISOTYPE  IN  HUMAN  ADCC  DIRECTED  BY  MURINE  mAb 
TABLE  III 
lgG2a ADCC Activities of Selected Lymphoid Populations 
Population  Percent 
of total 
ADCC at various E/T ratios 
(__SD) 
4:1  20:1  100:1 
Unseparated PBL  100  6 (1)  24 (2)  52 (3) 
Monocyte-depleted  95  6 (1)  31  (2)  57 (1) 
Leu-15 +  lymphocytes  29  15 (1)  52 (1)  NT 
Leu-15 -  lymphocytes  67  1 (1)  5 (3)  NT 
IgG2a ADCC activities of selected lymphoid populations. Unstained PBL 
were sorted on the basis of light scatter to exclude monocytes. In addition, 
PBL were stained with phycoerythrin-anti-Leu-15 and sorted on the basis 
of fluorescence  and  light  scatter.  The  three  sorted  populations  were 
compared with the untreated PBL at various E/T ratios for ADCC activity 
directed  by  4  ug/ml  IgG2a  ME1  against  SICr-labeled JY.  ADCC  was 
measured after 4  h  incubation at  37°C degrees.  Lymphocytes were de- 
pleted of monocytes by light scatter. NT, not tested. 
In contrast, cells not expressing Leu-15 had no ADCC activity, although these 
cells represented ~70% of the unfractionated PBL. 
Discussion 
In this study, we directly compared the activity of the IgG1, IgG2a, and !gG2b 
isotypes of otherwise identical mouse anti-HLA antibodies directing human PBL 
in ADCC against a B lymphoblastoid target. For antibodies of both the ME1 and 
MA2.1  switch variant families, we demonstrate that the IgG2a isotype is most 
effective,  IgG2b  less  effective,  and  IgG1  completely  ineffective  in  directing 
ADCC by human K cells. 
The  inactivity  of  IgG1  antibody  in  directing  ADCC  conflicts  with  some 
published reports of ADCC directed by this isotype (10, 43, 44).  In contrast to 
the IgG1 antibodies of both ME1  and MA2.1, the IgG1  antibody that directed 
high levels of ADCC  in one of these studies also directs efficient C-mediated 
cytolysis of antigen-bearing  cells (10).  Generally,  of the  murine  IgG isotypes, 
only IgG2a and IgG2b are effective in C=mediated lysis (30, 45).  In particular, 
this  is  true  for  antibodies  of both  MEI  and  MA2.1  switch  variant  families 
(unpublished observations).  Some mouse IgG1  antibodies,  however, can effec- 
tively fix C (46-48).  This may be due to unusual (variable-constant) V-C region 
interactions  or  posttranslational  modification of the  C  region.  This  may also 
explain, in part, why some IgG1  can direct ADCC by human K cells. Further- 
more, differences in the ADCC assay, such as higher E/T ratios, longer incuba- 
tion times, or different target cells, may permit IgG1 antibodies to direct ADCC. 
Our studies suggest, however, that an IgG2a antibody generally would be more 
effective than an  IgG1  antibody of the same specificity. This is in agreement 
with Hellstrom et al. (14) and Imai et al. (15), who noted greater effectiveness 
of murine IgG2a over IgG1 of like specificity in directing human PBL in ADCC 
against human melanoma cell lines. 
Our studies differ in several important respects from those of Steplewski et al. 
(13), who concluded that IgG2a is the only effective murine antibody isotype for KIPPS  ET  AL.  13 
directing  lysis  of  a  human  tumor  cell  line  by  human  effector  cells.  These 
investigators studied the effector activity of adherent PBL activated by weeks of 
in vitro culture. In contrast, the ADCC activities studied here are mediated by 
freshly isolated nonadherent Leu-15 + cells that are inhibited by anti-Leu-1 la, an 
antibody that does not react with monocyte FcR. 
Some of these differences may explain our finding of intermediate levels of 
ADCC  activity directed  by antibody of the  IgG2b  isotype,  in contrast  to .the 
apparent inactivity of this subclass reported by Steplewski et al. (13). Aside from 
the possibility that the IgG2b antibody studied by these investigators may not 
have the fine binding specificity and/or affinity necessary for directing ADCC, 
the differences noted in the activity of IgG2b could be related to differences in 
the FcR of the two effector populations studied. Several mAb, including Leu- 
1 la  (37),  are  specific  for  the  human  K  cell  FcR,  a  pronase-sensitive,  trypsin- 
resistant membrane protein of 52,000-58,000 mol wt (35, 47). These same mAb 
do not bind the human monocyte FcR, which has an apparent molecular weight 
of 72,000 (48).  However, it has been reported recently that 3G8, an mAb that 
reacts with an  FcR protein that co-modulates with Leu-1 la on human K  cells 
(37),  also  specifically  binds  a  protein  expressed  by  60%  of the  macrophages 
isolated from resected lung tissue (49).  This finding, plus the observation that 
the  antigen  detected  by  3G8  is  not  expressed  on  monocytes unless  they are 
cultured  in  vitro  for several  days,  supports the  idea  that  the  FcR  present on 
peripheral blood K cells is similar to or the same as that expressed on activated 
macrophages. 
Our data also indicate that human K cells interact preferentially with antibody 
bound to ceils. If free antibody readily bound to the effectors' FcR, saturation 
of available FcR would occur at high free antibody concentrations. This would 
give a  prozone effect with  diminished cytolysis of JY  by  PBL at  higher than 
saturating  concentrations of added antibody.  That  neither IgG2a  nor  IgG2b 
anti-HLA  Ig inhibit ADCC at high antibody concentrations, as seen in Figs. 4 
and  6,  shows  that  free  antibody cannot compete successfully with cell-bound 
antibody for FcR of human K cells. This is further supported by our inability to 
activate effector cells for ADCC of JY by precoating the PBL with the IgG2a 
ME1 or MA2.1. After washing away unbound antibody, these preincubated PBL 
had no cytolytic activity for uncoated JY,  although they still had the expected 
activity against IgG2a-coated JY (data not shown). 
In sharp contrast, others (14, 50-52) have demonstrated that there is a prozone 
effect when titrating  human ADCC activity with  increasing concentrations of 
added specific antibody. Several of these studies used antisera, not purified mAb, 
to direct ADCC (50-52). Titrations performed with such heterogenous mixtures 
would reflect the ADCC activities directed by unknown fractions of antibodies 
with different isotypes.  If, for example, a  high affinity antibody of an isotype 
capable  of directing  ADCC,  is  present  along  with  low  affinity  antibodies  of 
isotypes less active in directing ADCC, ADCC would be greater at low concen- 
trations of added antisera, where the binding of high affinity antibodies would 
be  favored.  Also,  without ultracentrifugation  of Ig samples before testing for 
ADCC (as we did in this study), preparations of mAb or antisera may contain Ig 
aggregates that would directly bind the FcR of effector cells. Such aggregates 14  Ig  ISOTYPE  IN  HUMAN  ADCC DIRECTED  BY  MURINE  mAb 
would compete with antibody bound to target cells and inhibit ADCC at higher 
serum concentrations. 
The vast differences in the capabilities of different isotypes of the ME1  and 
MA2.1  antibodies to direct ADCC in vitro makes us consider whether the in 
vivo biologic activity of a  particular mAb may be dependent upon its isotype. 
Studies comparing the activities of different isotypes derived from switch variant 
families in the immunotherapy of various human diseases need to be performed 
to test this hypothesis. 
Summary 
Using the fluorescence activated cell sorter to select rare IgG2a- and IgG2b- 
producing variants,  we developed switch variant families of hybridomas from 
IgG 1-producing hybridomas, ME 1 and MA2.1. The IgG2a and IgG2b antibodies 
produced by such switch variants have the same binding activities for HLA as 
the IgG 1 antibodies produced by the parent hybridomas. Using these antibodies, 
we directly compared the IgG 1, IgG2a, and IgG2b murine Ig isotypes for their 
capacities to  direct  human peripheral  blood  lymphocytes (PBL)  in  antibody- 
dependent cell-mediated cytotoxicity (ADCC) against a  B  lymphoblastoid cell 
line.  We  demonstrate  that,  for  antibodies  of identical  binding  affinity  and 
specificity, the murine IgG2a isotype is the most effective in directing ADCC by 
human effector cells.  The murine IgG2b directs intermediate levels of ADCC 
activity while IgG1  is inactive. We identified the effector cells in human PBL 
that mediate IgG2a or IgG2b ADCC as nonadherent killer (K) cells. These cells 
express the C3bi receptor and have cytolytic activity which is specifically blocked 
by a monoclonal antibody (anti-Leu-11 a) that binds the Fc receptor (FcR) of such 
cells.  Finally, FcR-bearing K cells bind to target cell-bound, rather than free, 
IgG2a or IgG2b molecules. 
We wish to thank Dr. Lewis Lanier for many helpful discussions. In addition, we thank 
Ms. Linda Lloyd for her help in preparing this manuscript for publication. 
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